[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361826-105":59,"doc-detail-361826-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-role-of-immunotherapy-in-targeting-tumor-microenvironment-in-genitourinary-cancers","The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers","","Genitourinary (GU) cancers—including renal cell carcinoma, prostate cancer, bladder cancer, and testicular cancer—remain a major cause of cancer mortality worldwide. Despite progress with chemotherapy, radiotherapy, and surgery, durable remission is hindered by the dynamic tumor microenvironment (TME), which includes diverse cell types, signaling molecules, and extracellular matrix components that drive progression, metastasis, and therapy resistance. Immunotherapy (IO) offers a targeted alternative by engaging immune mechanisms such as checkpoint inhibition, therapeutic vaccines, and adoptive cell transfer. This review summarizes current GU treatment strategies with an emphasis on IO approaches that specifically target TME cell populations and interactions, supporting more personalized outcomes and improved quality of life.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-of-immunotherapy-in-targeting-tumor-microenvironment-in-genitourinary-cancers/361826/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-of-immunotherapy-in-targeting-tumor-microenvironment-in-genitourinary-cancers/361826.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the role of the tumor microenvironment (TME) in genitourinary cancers?","Question",{"text":112,"@type":113},"The TME acts as a complex ecosystem of cancer cells, immune cells, stromal cells, cytokines, and extracellular matrix that supports cancer progression and metastasis. It also enables immune evasion, reducing long-term remission and affecting treatment effectiveness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does immunotherapy (IO) target genitourinary cancers differently from traditional treatments?",{"text":117,"@type":113},"IO leverages the immune system to counter cancer immune evasion, aiming to disrupt mechanisms such as checkpoint inhibition. It includes strategies like immune checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies that focus on interactions within the TME.",{"name":119,"@type":110,"acceptedAnswer":120},"Which immunotherapy approaches are highlighted as relevant to TME targeting?",{"text":121,"@type":113},"The review emphasizes checkpoint inhibition, therapeutic vaccines, and adoptive cell transfer therapies. These approaches are presented as mechanisms to target specific cell types and interactions in the TME to improve outcomes and quality of life.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361826,1790392959,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 07 April 2025  \nDOI 10.3389/fimmu.2025.1506278  \nOPEN ACCESS  \nEDITED BY  \nDerre´ Laurent,  \nCentre Hospitalier Universitaire Vaudois (CHUV), Switzerland  \nREVIEWED BY  \nLasse Dahl Ejby Jensen, Linköping University, Sweden Wen-Hao Xu,  \nFudan University, China Giuseppe Schepisi,  \nScientiﬁc Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy  \n*CORRESPONDENCE  \nMehmet Asim Bilen  \n [mehmet.a.bilen@emory.edu](mehmet.a.bilen@emory.edu)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 04 October 2024  \nACCEPTED 19 March 2025  \nPUBLISHED 07 April 2025  \nCITATION  \nKalemoglu E, Jani Y, Canaslan K and Bilen MA (2025) The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers.  \nFront. Immunol. 16:1506278 .  \ndoi: 10.3389/fimmu.2025.1506278  \nCOPYRIGHT  \n© 2025 Kalemoglu, Jani, Canaslan and Bilen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe role of immunotherapy in targeting tumor microenvironment in genitourinary cancers  \nEcem Kalemoglu 1,2†, Yash Jani 3†, Kubra Canaslan 4 and Mehmet Asim Bilen 5,6*  \n1 Department of Internal Medicine, Rutgers-Jersey City Medical Center, Jersey City, NJ, United States, 2 Department of Basic Oncology, Health Institute of Ege University, Izmir, Türkiye, 3 Medical College of Georgia, Augusta, GA, United States, 4 Department of Medical Oncology, Dokuz Eylul University, Izmir, Türkiye, 5 Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States, 6 Department of Urology, Emory University School of Medicine, Atlanta, GA, United States  \nGenitourinary (GU) cancers, including renal cell carcinoma, prostate cancer, bladder cancer, and testicular cancer, represent a signiﬁcant health burden and are among the leading causes of cancer-related mortality worldwide. Despite advancements in traditional treatment modalities such as chemotherapy, radiotherapy, and surgery, the complex interplay within the tumor microenvironment (TME) poses substantial hurdles to achieving durable remission and cure. The TME, characterized by its dynamic and multifaceted nature, comprises various cell types, signaling molecules, and the extracellular matrix, all of which are instrumental in cancer progression, metastasis, and therapy resistance. Recent breakthroughs in immunotherapy (IO) have opened a new era in the management of GU cancers, offering renewed hope by leveraging the body’s immune system to combat cancer more selectively and effectively. This approach, distinct from conventional therapies, aims to disrupt cancer ’s ability to evade immune detection through mechanisms such as checkpoint inhibition, therapeutic vaccines, and adoptive cell transfer therapies. These strategies highlight the shift towards personalized medicine, emphasizing the importance of understanding the intricate dynamics within the TME for the development of targeted treatments. This article provides an indepth overview of the current landscape of treatment strategies for GU cancers, with a focus on IO targeting the speciﬁc cell types of TME. By exploring the roles of various cell types within the TME and their impact on cancer progression, this review aims to underscore the transformative potential of IO strategies in TME targeting, offering more effective and personalized treatment options for patients with GU cancers, thereby improving outcomes and quality of life.  \nKEYWORDS  \nimmunotherapy (IO), immune checkpoint inhibitors (ICI), PD-1, PD-L1, T cells, genitourinary ca","cbCaif575BAbdm4Y","https://ap.wps.com/l/cbCaif575BAbdm4Y","pdf",4515850,31,"English","# Introduction\n## Genitourinary cancers\n## Tumor microenvironment (TME)\n## Immunotherapy (IO) targeting the TME","[{\"question\":\"What is the role of the tumor microenvironment (TME) in genitourinary cancers?\",\"answer\":\"The TME acts as a complex ecosystem of cancer cells, immune cells, stromal cells, cytokines, and extracellular matrix that supports cancer progression and metastasis. It also enables immune evasion, reducing long-term remission and affecting treatment effectiveness.\"},{\"question\":\"How does immunotherapy (IO) target genitourinary cancers differently from traditional treatments?\",\"answer\":\"IO leverages the immune system to counter cancer immune evasion, aiming to disrupt mechanisms such as checkpoint inhibition. It includes strategies like immune checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies that focus on interactions within the TME.\"},{\"question\":\"Which immunotherapy approaches are highlighted as relevant to TME targeting?\",\"answer\":\"The review emphasizes checkpoint inhibition, therapeutic vaccines, and adoptive cell transfer therapies. These approaches are presented as mechanisms to target specific cell types and interactions in the TME to improve outcomes and quality of life.\"}]","The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers | PDF",1790145703,78,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3275477f57983c115972f9dcbfb25f47.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d24adeedd0862ee49d51ae4acbcc1ac9.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49154770b282c4df31ac8e8498b6b995.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edbb33125b4658fa99add9844972a5f9.webp",980,1385]